LEADER

Systemic sclerosis

Predictors of end stage lung disease in systemic sclerosis

V Steen

Georgetown University, Washington DC, USA

Correspondence to:
Correspondence to:
Professor V Steen;
steenv@georgetown.edu

---

Recognition of the two types of lung disease is important because their predictors and treatment differ

---

Keywords: scleroderma; predictors; pulmonary function; manuscript submission

The first 150 words of the full text of this article appear below.

Pulmonary disease is now the leading cause of death in patients with scleroderma. Of the 2000 patients in the Pittsburgh scleroderma databank, 211 patients have died of lung disease over the past 20 years. One hundred and thirteen died from isolated pulmonary hypertension and 98 died of pulmonary interstitial fibrosis. These account for 21.5% of the 981 deaths and 44% of the scleroderma related deaths. Recently, progress has been made in the treatment of specific lung problems in scleroderma so it is imperative that we have a better understanding of the predictors of these complications. Most important is the acknowledgement and recognition that there are two types of lung disease in scleroderma which are very different in their pathogenesis, clinical associations, predictive factors, and treatment. The investigators of "Predictors of end stage lung disease in a cohort of patients with scleroderma" in this issue of the Annals admit . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Antoniou, K. M., Margaritopoulos, G., Economidou, F., Siafakas, N. M. (2009). Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 33: 882-896 [Abstract] [Full Text]  
• Vonk, M C, Marjanovic, Z, van den Hoogen, F H J, Zohar, S, Schattenberg, A V M B, Fibbe, W E, Larghero, J, Gluckman, E, Preijers, F W M B, van Dijk, A P J, Bax, J J, Roblot, P, van Riel, P L C M, van Laar, J M, Farge, D (2008). Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67: 98-104 [Abstract] [Full Text]  
• Lindqvist, P., Caidahl, K., Neuman-Andersen, G., Ozolins, C., Rantapaa-Dahlqvist, S., Waldenstrom, A., Kazzam, E. (2005). Disturbed Right Ventricular Diastolic Function in Patients With Systemic Sclerosis: A Doppler Tissue Imaging Study. Chest 128: 755-763 [Abstract] [Full Text]  
• Hachulla, E, Coghlan, J G (2004). A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 63: 1009-1014 [Abstract] [Full Text]  
• Braun, J., Sieper, J. (2004). Biological therapies in the spondyloarthritides--the current state. Rheumatology (Oxford) 43: 1072-1084 [Abstract] [Full Text]  
• Rudwaleit, M, Listing, J, Brandt, J, Braun, J, Sieper, J (2004). Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor {alpha} blockers in ankylosing spondylitis. Ann Rheum Dis 63: 665-670 [Abstract] [Full Text]